Bulletin
Investor Alert

New York Markets Close in:

Beam Therapeutics Inc.

NAS: BEAM

GO
/marketstate/country/us

Countdown to close

/zigman2/quotes/216229751/composite

$

63.17

Change

+0.33 +0.52%

Volume

Volume 1.27m

Jan 21, 2022, 3:55 p.m.

Real time quotes

/zigman2/quotes/216229751/composite

Previous close

$ 62.84

$ 63.17

Change

+0.33 +0.52%

Day low

Day high

$62.00

$67.70

Open
Open: 62.32

52 week low

52 week high

$56.34

$138.52

Open

Market cap

$4.28B

Average volume

706,982

P/E ratio

N/A

Rev. per Employee

$4,315

EPS

-6.69

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/beam

MarketWatch News on BEAM

  1. Luck Could Be Improving for the Battered Shares of Las Vegas Sands

    9:30 p.m. Jan. 14, 2022

    - Barron's Online

  2. Scientists Race to Make Really Big Changes to Your Genes

    2:23 p.m. Jan. 5, 2022

    - Barron's Online

  3. bluebird bio Has Good News on Its Gene Therapies

    12:16 p.m. Dec. 13, 2021

    - Barron's Online

  4. Beam Gets FDA Nod for First Gene-Editing Trial

    8:10 a.m. Nov. 9, 2021

    - Barron's Online

  5. Gene Therapy Is a Huge Opportunity. It Pays to be Patient.

    8:46 p.m. Nov. 5, 2021

    - Barron's Online

  6. Prime Is the Newest Gene Editing, and It's Getting Better

    6:11 p.m. Oct. 20, 2021

    - Barron's Online

  7. Beam Therapeutics assumed at buy, up from hold, at Stifel Nicolaus

    6:55 a.m. Sept. 24, 2021

    - Tomi Kilgore

  8. Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough

    8:21 a.m. June 30, 2021

    - Barron's Online

  9. How a Cloud Is Lifting from Bluebird and Other Gene Therapy Stocks

    12:38 p.m. June 7, 2021

    - Barron's Online

  10. Cathie Wood's ARK Innovation Is Rebounding. She Bought the Dip.

    1:39 p.m. May 28, 2021

    - Barron's Online

  11. Biotech stocks are a buy — especially these 18 picks

    1:02 p.m. March 13, 2021

    - Michael Brush

  12. Beam Therapeutics downgraded to neutral from overweight at J.P. Morgan

    7:18 a.m. Jan. 29, 2021

    - Tomi Kilgore

  13. Loading more headlines...
/news/nonmarketwatch/company/us/beam

Other News on BEAM

  1. It's Time To Go To Cash For The Next 7 Years - 1-Year Update

    2:41 p.m. Jan. 20, 2022

    - Seeking Alpha

  2. 11 Good And 4 Bad Reasons To Keep Holding ARK Invest

    3:42 p.m. Jan. 18, 2022

    - Seeking Alpha

  3. Former Alnylam CEO Maraganore joins Kymera Therapeutics board

    11:55 a.m. Jan. 18, 2022

    - Seeking Alpha

  4. Is Beam Therapeutics a Good Stock to Buy Now?

    6:47 a.m. Jan. 16, 2022

    - Motley Fool

  5. Why Editas Medicine Stock Is Tumbling This Week

    5:24 p.m. Jan. 13, 2022

    - Motley Fool

  6. My 3 Top Biotech Stock Picks for 2022

    2:00 p.m. Jan. 9, 2022

    - Motley Fool

  7. Genomic Medicine 2021: (Happy To) Turn The Page

    9:33 p.m. Jan. 4, 2022

    - Seeking Alpha

  8. Beam Therapeutics: An Early Company In A Promising Field

    1:17 p.m. Dec. 27, 2021

    - Seeking Alpha

  9. Intellia and gene editing rivals rally from recent slump

    3:02 p.m. Dec. 7, 2021

    - Seeking Alpha

  10. Loading more headlines...
/news/pressrelease/company/us/beam

Press Releases on BEAM

  1. Wednesday's ETF Movers: COPX, ARKG

    12:13 p.m. Jan. 12, 2022

    - MarketNewsVideo.com

  2. Loading more headlines...

Rates »

Link to MarketWatch's Slice.